Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination | Zendy

Esra KAYA KILIÇ | Zendy; Cemal Bulut | Zendy; Meli̇ha Çağla Sönmezer | Zendy; Özlem Ozel | Zendy; Çiğdem Ataman Hatipoğlu | Zendy; Günay Tuncer Ertem | Zendy; Necla Tülek | Zendy; Sami KINIKLI | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination

Author(s) -

Esra KAYA KILIÇ,

Cemal Bulut,

Meli̇ha Çağla Sönmezer,

Özlem Ozel,

Çiğdem Ataman Hatipoğlu,

Günay Tuncer Ertem,

Necla Tülek,

Sami KINIKLI

Publication year - 2019

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.10859

Subject(s) - linezolid , medicine , univariate analysis , neutropenia , combination therapy , platelet , gastroenterology , multivariate analysis , chemotherapy , vancomycin , biology , bacteria , genetics , staphylococcus aureus

Linezolid is a synthetic antimicrobial agent with a broad spectrum of activity against virtually all Gram-positive bacteria. Although linezolid is generally well tolerated, the prolonged use of linezolid can lead to myelosuppression, including neutropenia, thrombocytopenia, and anemia. The aim of this study was investigating the risk factors for thrombocytopenia in patients who received linezolid therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research